ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is treated with antibodies blocking epidermal growth factor receptor (EGF-R), but therapeutic success is limited. EGF-R is stimulated by soluble ligands, which are derived from transmembrane precursors by ADAM17-mediated proteolytic cleavage. In mouse intestinal cancer models in the absence of ADAM17, tumorigenesis was almost completely inhibited, and the few remaining tumors were of low-grade dysplasia. RNA sequencing analysis demonstrated down-regulation of STAT3 and Wnt pathway components. Because EGF-R on myeloid cells, but not on intestinal epithelial cells, is required for intestinal cancer and because IL-6 is induced via EGF-R stimulation, we analyzed the role of IL-6 signaling. Tumor formation was equally impaired in IL-6−/− mice and sgp130Fc transgenic mice, in which only trans-signaling via soluble IL-6R is abrogated. ADAM17 is needed for EGF-R–mediated induction of IL-6 synthesis, which via IL-6 trans-signaling induces β-catenin–dependent tumorigenesis. Our data reveal the possibility of a novel strategy for treatment of colorectal cancer that could circumvent intrinsic and acquired resistance to EGF-R blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 3×
“On target cells, IL-6 binds to the IL-6 receptor (IL-6R), and the complex of IL-6 and IL-6R binds to the ubiquitously expressed signaling receptor subunit gp130, which upon dimerization initiates intracellular signaling via the STAT3 and ERK pathways (Scheller et al., 2011b).”
BackgroundSelf-citationA metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149 · cited 1×
“This cleavage is performed by members of the ADAM (a disintegrin and metalloprotease) family, with most ligands cleaved by the protease ADAM17, which is a membrane-bound metalloprotease (Black et al., 1997; Moss et al., 1997).”
BackgroundA subcellular map of the human proteome
Thul, P. J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Björk, L., Breckels, L. M., et al. (2017) · Science · doi:10.1126/science.aal3321 · Cited by 2,813 · cited 2×
“This was not completely unexpected, since ADAM17 mRNA is found in virtually all cells (Scheller et al., 2011a; Thul et al., 2017) and regulation of ADAM17 activity occurs mainly at the posttranslational level (Li et al., 2015; Sommer et al., 2016; Grieve et al., 2017).”
BackgroundGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationTerzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974 · cited 2×
“Chronic intestinal inflammation (Terzic et al., 2010) and elevated activity of epidermal growth factor receptor (EGFR) have been associated with increased risk of CRC (Sibilia et al.”
BackgroundAtreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationDiet, microorganisms and their metabolites, and colon cancer
O'Keefe, S. J. D. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.165 · Cited by 1,100
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing
Pickert, G., Neufert, C., Leppkes, M., Zheng, Y., Wittkopf, N., Warntjen, M., Lehr, H.-A., Hirth, S., Weigmann, B., Wirtz, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082683 · Cited by 1,043 · cited 2×
“We next tested for known Wnt and STAT3 target genes (https:// web .stanford .edu/ group/ nusselab/ cgi -bin/ wnt/ target _genes; Pickert et al., 2009) and found several of them significantly more highly expressed in ApcMin/+ mice compared with ApcMin/+::ADAM17ex/ex mice (Table 1), again indicating…”
BackgroundMethodLesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Self-citationLinardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739 · cited 1×
“However, it is now clear that EGF-R–blocking antibodies, including cetuximab or pantuximab, are beneficial only in patients who do not harbor KRAS mutations (Linardou et al., 2008; Tobin et al., 2015).”
BackgroundMauer, J., Chaurasia, B., Goldau, J., Vogt, M. C., Ruud, J., Nguyen, K. D., Theurich, S., Hausen, A. C., Schmitz, J., Brönneke, H. S., et al. (2014) · Nature Immunology · doi:10.1038/ni.2865 · Cited by 727 · cited 1×
“Interestingly, differentiation of M2 macrophages requires IL-6 signaling via the membrane-bound IL-6R (Mauer et al., 2014), pointing to a plausible link between EGF-R and IL-6 in the intestine.”
BackgroundA gp130–Src–YAP module links inflammation to epithelial regeneration
Taniguchi, K., Wu, L.-W., Grivennikov, S. I., de Jong, P. R., Lian, I., Yu, F.-X., Wang, K., Ho, S. B., Boland, B. S., Chang, J. T., et al. (2015) · Nature · doi:10.1038/nature14228 · Cited by 633
β-Catenin destruction complex: insights and questions from a structural perspective
Kimelman, D., & Xu, W. (2006) · Oncogene · doi:10.1038/sj.onc.1210055 · Cited by 628 · cited 1×
“Loss of the remaining Apc WT allele leads to ligand-independent activation of the canonical Wnt signaling cascade, nuclear accumulation of β-catenin, and development of intestinal adenomas primarily in the small intestine (Kimelman and Xu, 2006).”
BackgroundFrequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P., & Zucman-Rossi, J. (2009) · Nature · doi:10.1038/nature07475 · Cited by 477 · cited 1×
“Frequent somatic activating mutations in gp130 have been detected in inflammatory hepatocellular adenomas (Rebouissou et al., 2009).”
BackgroundThe role of IL-6 in host defence against infections: immunobiology and clinical implications
Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424 · cited 2×
“As such, ADAM17 regulates the IL-6 trans-signaling pathway through generation of the soluble IL-6R (sIL-6R; Yan et al., 2016), which drives most of the proinflammatory activities of the cytokine IL-6 (Rose-John et al., 2017).”
BackgroundSelf-citationKraakman, M. J., Kammoun, H. L., Allen, T. L., Deswaerte, V., Henstridge, D. C., Estevez, E., Matthews, V. B., Neill, B., White, D. A., Murphy, A. J., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.006 · Cited by 257 · cited 1×
“These mice were shown to be completely resistant to IL-6 trans-signaling–mediated pathologies (Lesina et al., 2011; Kraakman et al., 2015; Bergmann et al., 2017).”
BackgroundSelf-citationPietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182
IL‐6 trans‐signaling is essential for the development of hepatocellular carcinoma in mice
Bergmann, J., Müller, M., Baumann, N., Reichert, M., Heneweer, C., Bolik, J., Lücke, K., Gruber, S., Carambia, A., Boretius, S., et al. (2017) · Hepatology · doi:10.1002/hep.28874 · Cited by 152 · cited 1×
“These mice were shown to be completely resistant to IL-6 trans-signaling–mediated pathologies (Lesina et al., 2011; Kraakman et al., 2015; Bergmann et al., 2017).”
BackgroundSelf-citationTsukamoto, H., Fujieda, K., Hirayama, M., Ikeda, T., Yuno, A., Matsumura, K., Fukuma, D., Araki, K., Mizuta, H., Nakayama, H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2446 · Cited by 53 · cited 2×
“As we have shown, EGF-R stimulation of CD11b-positive colonic myeloid cells led to massive IL-6 induction (Srivatsa et al., 2017), and sIL-6R is generated by these cells (Tsukamoto et al., 2017).”
Background
Cited by
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Self-citationTherapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
Self-citationLichtenthaler, S. F., Lemberg, M. K., & Fluhrer, R. (2018) · The EMBO Journal · doi:10.15252/embj.201899456 · Cited by 323
Kruse, T., Gnosa, S. P., Nasa, I., Garvanska, D. H., Hein, J. B., Nguyen, H., Samsøe‐Petersen, J., Lopez‐Mendez, B., Hertz, E. P. T., Schwarz, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103695 · Cited by 97
Self-citation
Metadata
- Authors
- Schmidt, S., Schumacher, N., Schwarz, J., Tangermann, S., Kenner, L., Schlederer, M., Sibilia, M., Linder, M., Altendorf-Hofmann, A., Knösel, T., Gruber, E. S., Oberhuber, G., Bolik, J., Rehman, A., Sinha, A., Lokau, J., Arnold, P., Cabron, A.-S., Zunke, F., Becker-Pauly, C., Preaudet, A., Nguyen, P., Huynh, J., Afshar-Sterle, S., Chand, A. L., Westermann, J., Dempsey, P. J., Garbers, C., Schmidt-Arras, D., Rosenstiel, P., Putoczki, T., Ernst, M., & Rose-John, S.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2018-02-22
- Volume
- 215
- Issue
- 4
- Pages
- 1205-1225
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2793384878
- Cited by
- 80
- References
- 21
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.